Bard PowerPort Settlement Plan: Parties Ask Judge to Close MDL 3081 and Park Cases on an Inactive Docket
There is no Bard PowerPort settlement yet, but there is now a timetable for one: Bard and plaintiffs' leaders jointly asked the MDL 3081 judge to close the MDL to new direct filings on February 28, 2027, park every pending case on an inactive docket, and negotiate deals by September 1, 2027.
Torts Desk··20 min read

There is still no Bard PowerPort settlement, but for the first time there is a court filing that maps how one would be reached: C.R. Bard and the plaintiffs in MDL No. 3081 have jointly asked Senior Judge David G. Campbell to close the federal port catheter MDL to new direct filings on February 28, 2027, move every pending case to an inactive docket after the last bellwether trial, and give the parties until September 1, 2027 to negotiate settlements. Mealey's reported the joint proposal on November 13, 2026; if the judge adopts it, the roughly 4,345 federal cases stop moving toward trial and start moving toward a negotiating table, with a hard date attached.
The proposal does not set a price, create a fund or bind any claimant. It sets a calendar. That matters because calendars are what turn a stalled mass tort into a resolved one: the same judge used settlement tracks and remand orders to wind down Bard's IVC filter MDL between 2019 and 2021, and Bard's pelvic mesh MDL in West Virginia ran an inactive docket for settled cases until the court shut it to new entries in late 2018.
This article explains what the joint proposal contains, what an inactive docket does and does not do, what happens to new cases after February 2027 and to cases that do not settle by September 2027, how Bard has wound down its earlier MDLs, what the bellwether record says about leverage, and what the plan means for claimants' counsel, Bard, funders and lienholders.
Is there a Bard PowerPort settlement?
No. As of November 14, 2026, Bard and its parent Becton Dickinson have not announced a Global Settlement of the port catheter litigation, and no Settlement Matrix, Qualified Settlement Fund (QSF), Claims Administrator or per-claim value has been disclosed. Every report on the November filing, including Mealey's, AboutLawsuits and the TorHoerman Law update, describes it as a joint proposal for a settlement process, not as an agreement to pay.
What has changed is the posture. Until this month, the Bard PowerPort lawsuit had been run on the trial track: a bellwether pool, four trial settings, a stream of Rule 702 and summary judgment rulings, and a case count that has grown every month since the Judicial Panel on Multidistrict Litigation (JPML) centralized the cases in Phoenix in August 2023. The joint proposal is the first public sign that both sides are planning for the end of that track and for a negotiated exit from it.
The phrasing in the reports is careful for a reason. A joint scheduling proposal from leadership counsel and a defendant is common in mature MDLs and says nothing about whether a deal will be reached, at what value, or with what participation threshold. It does say that both sides expect the bellwether program to have done its job by early 2027, and that neither side wants the federal docket to keep growing while they negotiate.
Who would the Bard PowerPort settlement plan cover?
The plan, as reported, covers every case pending in In re Bard Implanted Port Catheter Products Liability Litigation, MDL No. 3081, in the District of Arizona. Those are personal injury claims against C.R. Bard, Bard Access Systems and Becton Dickinson by patients who received an implanted port, a small reservoir placed under the skin of the chest or arm and connected to a catheter that runs into a large vein, typically to deliver chemotherapy, antibiotics or nutrition over months or years.
The claims share a common defect theory. Plaintiffs allege that the catheters were made with barium sulfate, added so that the tubing shows up on imaging, in a way that degrades the integrity of the catheter material over time. The New Jersey Supreme Court's order creating the state-court MCL summarizes the allegation in those terms, and Bard denies that any legal or medical basis supports it. According to plaintiffs, the degradation leads to cracking and fracture, to fragments migrating through the bloodstream, and to surface changes that encourage bacterial colonization and clot formation. The injury categories in the litigation therefore fall into four broad groups: fracture, migration, infection and thrombosis.
Those categories matter for the settlement plan in two ways. They are the categories the bellwether program was built to test, which is why the court selected cases representing different injuries rather than the strongest or weakest individual claims. And they are likely to be the categories any eventual matrix uses to sort claims into payment tiers. A claimant's place in that structure will depend on which injury the medical records document, whether the device had to be surgically removed, and how clearly the records identify a Bard product, rather than one made by another manufacturer, as the device implanted.
The plan would not cover claims against other port makers. AngioDynamics port catheter claims are centralized separately, in MDL No. 3125, and nothing in the reported Bard proposal addresses them. Nor would it, by its own force, cover the New Jersey MCL cases or other state-court actions, although any global deal Bard negotiates could be drafted to include them.
What is the Bard PowerPort inactive docket proposal?
The proposal has four moving parts, according to the published reports. First, the MDL court would stop accepting new direct-filed cases on February 28, 2027. Second, once the final Bellwether Trial concludes and the filing cutoff passes, all pending cases in MDL 3081 would be placed on an inactive docket, suspending further proceedings in them. Third, the parties would have until September 1, 2027 to negotiate settlement agreements covering some or all of the inactive cases. Fourth, cases resolved by agreement before that date would remain inactive until March 1, 2028, to give the parties time to complete releases, lien resolution and dismissals.
AboutLawsuits also reports that the proposal sets out procedures for preserving videotaped testimony from certain witnesses during 2027. The reports do not identify the witnesses. In a litigation that may later be broken up and sent back to courts across the country, recorded trial testimony is a way to avoid calling the same corporate and expert witnesses live in dozens of separate trials.
| Proposed date | Event under the joint proposal | Source |
|---|---|---|
| November 6, 2026 | Joint proposal filed in MDL 3081 | AboutLawsuits |
| December 1, 2026 | Hicks v. Bard bellwether trial (thrombosis) scheduled to open | Court schedule, multiple reports |
| February 2027 | Final scheduled bellwether trial (reported as February 2, 2027; one tracker gives February 19) | AboutLawsuits, Drugwatch |
| February 28, 2027 | MDL closes to new direct-filed short-form complaints | Mealey's, AboutLawsuits |
| After final bellwether and cutoff | All pending cases move to an inactive docket | Mealey's, TorHoerman |
| 2027 | Videotaped preservation testimony of certain witnesses | AboutLawsuits |
| September 1, 2027 | Deadline to negotiate settlements for inactive cases | AboutLawsuits, TorHoerman |
| March 1, 2028 | Settled cases stay inactive until this date for paperwork and dismissals | TorHoerman |
None of these dates is yet an order. Judge Campbell had not ruled on the proposal when it was reported, and judges in his position often adopt joint schedules with changes, especially to provisions that affect claimants who are not yet represented or not yet on file.
When will the Bard PowerPort MDL close to new cases?
Under the proposal, February 28, 2027 is the last day a new case could be filed directly into MDL 3081. Mealey's describes the request as one to "close the MDL" by that date; AboutLawsuits describes the same date as the point after which the court would no longer accept the short-form complaints used for direct filing. The two descriptions are consistent in effect: after February 28, 2027, the Arizona MDL would stop taking new port catheter cases through its streamlined filing channel.
Direct filing is a convenience the MDL court created, not a right. Under the court's Third Amended Case Management Order No. 7, which governs the master complaint, master answer, direct filing and short-form complaints, a claimant whose case would otherwise be transferred into the MDL may file it straight into the District of Arizona on a short-form complaint, and must state the district where personal jurisdiction and venue would have been proper absent direct filing. That designated home district matters later, because it is where a case is likely to go if it is remanded or transferred out of the MDL.
Ending direct filing is the standard first step in closing a mature MDL. It fixes the size of the federal inventory, which both sides need to price a deal, and it ends the monthly growth that has characterized MDL 3081. The JPML's November 2, 2026 statistics report listed 4,345 pending actions, up 205 from the previous month. A defendant negotiating a global deal wants to know how many claims it is buying peace from, and leadership counsel wants to know how many clients will share whatever is negotiated.
Can new Bard PowerPort lawsuits be filed after February 2027?
Yes, but not by direct filing into the MDL. Closing MDL 3081 to direct filing would not prevent new port catheter lawsuits from being filed in any other court with jurisdiction and venue, as the TorHoerman update notes. A claimant could still sue in a state court that has jurisdiction over Bard, or in a federal district court where venue is proper.
Three practical points follow.
First, a newly filed federal case would not automatically join the MDL. Under 28 U.S.C. § 1407, the JPML transfers related federal cases into an MDL as "tag-along" actions. Whether the panel or the transferee court would still accept tag-alongs after the MDL closes, or whether new federal cases would be litigated in their home districts, is a question the published reports do not answer and that the final order may address.
Second, there is a functioning state-court alternative. On October 15, 2024, the New Jersey Supreme Court designated the Bard implanted port catheter cases as a multicounty litigation, MCL No. 640, assigned to Bergen County under Superior Court Judge Gregg A. Padovano, with master docket BER-L-2403-25. Bard's parent, Becton Dickinson, is headquartered in New Jersey, which makes that forum available for claimants from many states. Nothing in the federal joint proposal, as reported, binds the New Jersey court.
Third, the real deadline for most claimants is not the MDL cutoff but the Statute of Limitations in their own state, together with any Statute of Repose and the Discovery Rule that governs when a claim accrues. Personal injury limitations periods in product cases commonly run from one to six years depending on the state. A claimant whose catheter fractured, migrated or caused an infection or clot in 2025 may still have time after February 2027 in some states and not in others. The MDL cutoff does not extend or shorten any of those periods. Practitioners holding unfiled claims will be checking whether any Tolling Agreement covering port claims exists; none has been publicly reported.
What happens to Bard PowerPort cases on the inactive docket?
An inactive docket is a case management device, not a disposition. Cases placed on it stay pending, keep their filing dates and remain under the MDL court's jurisdiction, but ordinary pretrial obligations stop: no new discovery deadlines, no case-specific expert schedules, no trial settings. The point is to stop the litigation clock while the parties negotiate, so that neither side has to spend money preparing thousands of individual cases that may settle.
Under the reported proposal, every pending MDL 3081 case would go onto the inactive docket after the final bellwether trial and the February 28 cutoff. Cases that settle by September 1, 2027 would remain inactive until March 1, 2028. That six-month tail is for the work that follows any mass tort deal: claim documentation, releases, resolution of each Medical Lien held by Medicare, Medicaid and private health plans, probate approvals for deceased claimants, and stipulated dismissals once money is paid.
The inactive docket does not decide the merits of any claim, does not waive any defense and does not, on its own, compel anyone to settle. It also does not, as reported, relieve plaintiffs of fact-sheet obligations already owed. MDL courts that run inactive dockets usually condition placement on compliance with existing Plaintiff Fact Sheet (PFS) and records-production orders, because a defendant cannot price a claim it cannot see. Whether the final order in MDL 3081 includes such conditions is one of the details to watch.
The inactive docket is also distinct from a Lone Pine Order, which requires each plaintiff to produce prima facie evidence of exposure, injury and causation on pain of dismissal. Lone Pine orders are often entered after a settlement program closes, to clear out the claims that did not participate. The reported Bard proposal contains no Lone Pine mechanism. That could change if a deal is reached and participation falls short.
What happens if a Bard PowerPort case does not settle by September 2027?
The published reports do not say what the proposal provides for cases that remain unresolved after September 1, 2027. Precedent from the same judge points to the likely answer. In Bard's IVC filter litigation, MDL 2641, Judge Campbell's Case Management Orders 41 and 42 in 2019 placed cases on separate settlement tracks, under which a case either settled or was prepared for remand. On August 20, 2019, the court issued its first suggestion of remand, sending 35 cases back to their transferor courts after finding that thousands of cases had settled or were close to settlement and that the remaining cases no longer benefited from centralized proceedings. Further suggestions of remand followed, and an April 2021 order stated that the MDL had concluded, with every remaining case settled, dismissed with prejudice, or remanded or transferred to its home court.
If MDL 3081 follows that model, cases that do not settle would be returned to the districts from which they came, or for direct-filed cases, transferred to the district named in the short-form complaint, to be prepared for trial individually. That is where the videotaped-testimony provision would pay off. Remand courts would have recorded testimony from key witnesses, and the general liability discovery taken in the MDL would travel with each case.
A remand, though, is a decision for the transferee judge and the JPML, not something the parties can agree into existence. Until an order issues, the post-September 2027 path remains a matter of inference from precedent.
How has Bard wound down its earlier mass tort MDLs?
Bard is a repeat MDL defendant, and two of its earlier dockets show the playbook it and the courts have used before.
In the pelvic mesh litigation, In re C.R. Bard, Inc. Pelvic Repair System Products Liability Litigation, MDL 2187 in the Southern District of West Virginia, the court ran an inactive docket for cases the parties reported as settled. Pretrial Order No. 282 in 2018 addressed the dismissal of settled and paid cases from that docket. Pretrial Order No. 296, entered in October 2018, stopped the court from accepting new cases onto the inactive docket on or after November 1, 2018, and set staged deadlines: cases placed on the docket from July through December 2017 had to be dismissed by January 30, 2019, and those placed from January through October 2018 by April 29, 2019, with unresolved cases returned to the active docket on compressed schedules. The lesson is that an inactive docket runs on deadlines, and a court will eventually force each parked case to settle, be dismissed or go back to active litigation.
In the IVC filter litigation, MDL 2641 in the District of Arizona, Judge Campbell presided over bellwether trials, then over a settlement process run through case management orders, and then over a sequence of remand and transfer orders that closed the MDL in 2021. The port catheter MDL is before the same judge, in the same courthouse, against the same defendant, with some of the same lawyers.
A third precedent, from a different defendant, shows the other use of an inactive or administrative docket. In the 3M Combat Arms earplug MDL, No. 2885 in the Northern District of Florida, hundreds of thousands of claims sat on an administrative docket, and the court in May 2022 ordered more than 20,000 of them moved to the active docket within 30 to 60 days or face dismissal. That pressure preceded 3M's 2023 settlement of about $6 billion, consisting of $5 billion in cash and $1 billion in stock paid through 2029.
| MDL | Defendant / court | Docket device | How it ended |
|---|---|---|---|
| 2187 (pelvic mesh) | C.R. Bard / S.D. W. Va. | Inactive docket for settled cases; closed to new entries Nov. 1, 2018 (PTO 296) | Staged dismissal deadlines in 2019; unresolved cases returned to active docket |
| 2641 (IVC filters) | C.R. Bard / D. Ariz., Judge Campbell | Settlement tracks (CMOs 41-42, 2019) | Suggestions of remand from Aug. 20, 2019; MDL concluded April 2021 |
| 2885 (combat earplugs) | 3M / N.D. Fla. | Administrative docket; batches moved to active docket from 2022 | About $6 billion global settlement in 2023 |
| 3081 (port catheters) | C.R. Bard / D. Ariz., Judge Campbell | Proposed inactive docket after final bellwether | Proposed settlement window to Sept. 1, 2027; not yet ordered |
What does the bellwether record mean for the Bard PowerPort settlement?
Bellwether verdicts set the price range for a mass tort deal, and the PowerPort bellwether record is mixed. The first trial, Cook, ended in May 2026 with the jury finding Bard not negligent on the failure-to-warn and instructions claims and deadlocking on the design defect claim. The second, Divelbliss, a catheter fracture case, produced a $40 million compensatory verdict for the plaintiff on September 4, 2026, with no punitive damages; judgment was entered September 10, and Bard moved for a new trial on October 8. The third, Lattanzio, a Florida infection case, ended in a defense verdict on October 30, 2026.
| Bellwether | Injury type | Result | Date |
|---|---|---|---|
| Cook | Infection | No negligence on warnings and instructions; hung jury on design defect | May 2026 |
| Divelbliss | Catheter fracture | $40 million compensatory verdict for plaintiff | September 4, 2026 |
| Lattanzio | Infection | Defense verdict | October 30, 2026 |
| Hicks | Thrombosis | Set for trial | December 1, 2026 |
| Final bellwether (reported as Sorensen) | Not detailed in public reports | Set for trial | February 2027 |
That record, two defense results against one large plaintiff verdict, shapes the leverage both sides bring to the September 2027 deadline. It suggests that infection claims, where Bard has twice persuaded juries that the patient's illness or clinical care rather than the device caused the harm, will be valued differently from fracture and migration claims, where the only verdict so far is the $40 million Divelbliss award. Any eventual Settlement Matrix in a device MDL typically sorts claims by injury category, severity, need for surgical removal, and proof of product identification and causation, and the bellwether results will feed directly into those tiers.
When is the next Bard PowerPort bellwether trial?
The next trial is Hicks v. Bard, No. 2:23-cv-01703, a Missouri thrombosis case set to open in Phoenix on December 1, 2026. Judge Campbell denied Bard's summary judgment motion in Hicks on October 26, 2026, and later granted the plaintiff summary judgment on certain of Bard's affirmative defenses while allowing Bard to argue that catheter placement, rather than a defect, caused her blood clot. It is the first thrombosis bellwether in the litigation. A final bellwether trial is reported for February 2027; AboutLawsuits identifies the case as Sorensen, and trackers differ on whether it opens on February 2 or February 19.
Because the proposal puts all cases on the inactive docket only after the final bellwether concludes, both remaining trials still matter. A plaintiff win in Hicks would give thrombosis claimants their first verdict benchmark; a defense win would extend Bard's run and pressure values across injury categories.
How much is a Bard PowerPort settlement worth per person?
No one knows, because no settlement exists. There is no matrix, no fund and no announced aggregate figure. Ranges that circulate online, such as Drugwatch's report that attorneys estimate PowerPort settlements could fall between $10,000 and $300,000 per case, are projections, not terms, and should not be read as offers.
What can be said is how value will likely be set. Device MDL settlements generally pay more for injuries that required surgery to remove a fractured or migrated catheter, for serious infections requiring hospitalization, and for thrombosis that caused lasting harm, and less for claims with weak product identification, long gaps between implant and injury, or significant alternative causes. Claims may also be reduced for Common Benefit Fund assessments that compensate the MDL's leadership for shared work, for each claimant's Contingency Fee, and for lien repayments. A claimant's net recovery will depend on all of those deductions, not only on the gross matrix value.
Aggregate exposure is the other unknown. The case count is public; Bard's internal valuation is not. Becton Dickinson has not, in the reporting reviewed for this article, disclosed a specific accrual for the port catheter litigation.
Why would Bard and plaintiffs agree to an inactive docket now?
Both sides gain something from a fixed calendar. For Bard, closing direct filing caps the federal inventory, which has grown by roughly 200 cases a month, and parking the cases ends the cost of preparing thousands of individual claims for discovery and trial. For plaintiffs' leadership, a September 1, 2027 negotiating deadline creates a defined window in which the defendant has committed to talk, without giving up the threat of remand trials for any case that does not settle.
The timing also reflects the bellwether calendar. By the end of February 2027, the court will have tried, or set for trial, cases representing each of the major injury theories that have been tried or set so far: infection, fracture and thrombosis. After that, additional bellwethers add cost without adding much new information about how juries value each category. Moving to settlement after a representative set of trials is the outcome the bellwether process is designed to produce, and it tracks what Federal Rule of Civil Procedure 16.1, which took effect on December 1, 2025, asks MDL courts to take up at the initial management conference: whether the court should consider measures to facilitate settlement of some or all of the actions.
There is also an argument for doing it in the open. A joint proposal on the public docket tells unrepresented claimants, referring lawyers and state-court counsel that the federal window is closing, which reduces later disputes over notice and fairness.
What it means for claimants' counsel, Bard, funders and lienholders
For claimants' counsel with unfiled cases, the February 28, 2027 date is the practical deadline to get into the federal MDL's settlement pool through direct filing, assuming the judge adopts it. After that, a case would have to be filed elsewhere, such as in a home-state court or the New Jersey MCL, and may sit outside whatever framework is negotiated for the inactive docket. Firms are likely to audit inventories now for limitations exposure, product identification records, and implant and explant documentation, because those are the records a matrix will demand.
For counsel with filed cases, the inactive docket is not a pause in the work. Fact sheets, medical records and lien information will drive valuation. Clients will need to be told that the proposal is a schedule, not a settlement, and that no figure exists.
For Bard and Becton Dickinson, the plan converts an open-ended trial docket into a negotiation with a deadline, while preserving defense positions in Hicks and the February trial. The videotaped-testimony provision protects against the cost of repeated live testimony if a meaningful number of cases do not settle and are remanded.
For litigation funders and lenders holding Bard port inventory, the timeline offers a horizon: a negotiating deadline in September 2027 and a paperwork tail into March 2028 suggest that payments, if a deal is reached, would not flow before late 2027 at the earliest. Third-Party Litigation Funding agreements priced on earlier resolution assumptions may need to be revisited, and the mixed bellwether record argues for discounting infection claims relative to fracture claims.
For Medicare, Medicaid and private health plans, the March 1, 2028 tail is when lien resolution will happen. Plans that have paid for port removals, infection treatment or anticoagulation will want their recovery rights identified before any Qualified Settlement Fund (QSF) disburses.
For state-court judges and counsel, particularly in the New Jersey MCL, the federal plan may shift new filings toward state forums after February 2027, and any global deal would need to address whether state-court plaintiffs may participate.
Frequently asked questions
Is there a Bard PowerPort settlement?
No. As of November 14, 2026, there is no global settlement, settlement fund or announced per-claim value. The parties have jointly proposed a process that would give them until September 1, 2027 to negotiate settlements, but the judge had not approved even that process when it was reported.
What is the Bard PowerPort inactive docket?
It is a proposed case management step under which all pending MDL 3081 cases would be suspended after the final bellwether trial, so the parties can negotiate without ongoing pretrial deadlines. Cases on an inactive docket stay pending; they are not dismissed.
When is the deadline to join the Bard PowerPort MDL?
Under the joint proposal, the MDL would stop accepting new direct-filed short-form complaints on February 28, 2027. The proposal has not yet been adopted, and each claimant's state statute of limitations may expire earlier.
Can I still sue Bard after the MDL closes?
Under the reported proposal, yes, in another court with jurisdiction and venue, such as a state court or the New Jersey multicounty litigation in Bergen County. A late-filed case may fall outside any federal settlement framework, and the state statute of limitations still applies.
What happens to Bard PowerPort cases that do not settle?
The reports do not specify. In Bard's IVC filter MDL, the same judge sent unresolved cases back to their home courts through suggestions of remand once settlement tracks had run, and a similar path is plausible here.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Bard PowerPort Lawsuit Update: Judge Strikes Some Bard Defenses but Keeps Catheter-Placement Theory for Trial
The latest Bard PowerPort lawsuit update: the MDL 3081 judge granted a bellwether plaintiff summary judgment on certain affirmative defenses but will let Bard tell the jury that catheter placement, not a defect, caused her blood clot. The Hicks thrombosis trial opens December 1.
Torts Desk · 20 min

Bard PowerPort Verdict: Jury Clears Bard in Lattanzio Infection Bellwether, Scorecard Now 2-1
A Phoenix federal jury returned a defense verdict on October 30, 2026 in Lattanzio, the third Bard PowerPort bellwether and the second infection case tried in MDL 3081. Infection claims are now 0-2 at trial, and the $40 million fracture verdict stands alone.
Torts Desk · 21 min

MDL Statistics November 2026: Uber's Pending Count Falls 368 as Social Media MDL Adds 485
The JPML's MDL statistics for November 2026 list 164 dockets, with J&J talc still largest at 69,376 actions. Uber's sexual assault MDL lost 368 pending cases while filings kept coming, social media addiction jumped 485, and hair relaxer passed 12,700.
Torts Desk · 22 min